Reading and Writing a Book With DNA

16 August 2012Harvard University researchers converted a 53 000-word book into DNA and then read the DNA-encoded book using gene-sequencing technology, the researchers report this week in Science. The project is by far the largest demonstration of digital information storage in DNA and the densest consolidation of data in any medium, the authors say.

There is a clear need for improved long-term storage of massively large data, says George Church, a geneticist at Harvards Wyss Institute and one of the leaders of the research. There is data that we are throwing away or dont collect because we cant afford to store it, such as video surveillance of public spaces and large research projects, he says. Someday that wont be necessary. The question is, What will get us there first: electronic or molecular memory?

DNA offers advantages over electronic storage, but whether it will ever make sense practically or economically is unclear. DNA can store more digital information per cubic millimeter than flash memory or even cutting-edge experimental memories such as quantum holography. Data stored in DNA is also recoverable for millennia (consider the 7000-year-old DNA archaeologists have extracted from human remains). And given DNAs biological importance, we can safely assume its going to remain a readable standard for a long time. If you look at the size per bit of stored memory as DNA, its unlikely that well ever get better than that, says Joseph Jacobson, a synthetic biologist at MIT who was not involved in the project.

But making and reading DNA isnt yet practical. Synthesizing and sequencing DNA is expensive, although the cost for both of these technologies has been dropping at a rate of five- and twelvefold per year, respectively. Whats more, unlike electronic bits, most DNA data cannot be changed once its written. And with todays technology, information in DNA usually has to be accessed as a whole, not in parts. (There is no way to make random-access DNA memory.)

Church and his colleagues set out to demonstrate a simple way to densely store data in DNA. They converted an html draft of a book comprising 53 426 words, 11 JPG images, and one JavaScript program into a 5.27 megabit set of zeros and ones. Using software they wrote, zeros were assigned the letter A or C for the DNA bases adenine and cytosine, and ones were assigned the letter G or T for DNA bases guanine and thymine. A lowercase f from the book, for example, was represented in binary as 01100110 and encoded in DNA as ATGAATTC.

Synthesizing that string of bits would yield a stretch of DNA that was 5.27 million bases long. Such long stretches of DNA are particularly expensive to work with, so Church and his colleagues split the DNA sequence into short chunks that were each 96 bases long. Each chunk included a 19-bit bar code, or address, to show where that chunk belonged in the whole of the book. The DNA was synthesized, inkjet-printed on a glass DNA microchip, and then cleaved off and dried to form a 50-nanogram clump smaller than a speck of pollen.

To convert the DNA back to a book, Church and his colleagues read out the bases using commercially available sequencing technology. They then arranged the sequence, decoded it back to zeros and ones, and converted those back to an HTML book. The researchers were able to complete the project with errors in only 10 bits out of 5.27 millionon par with the raw error rate of other storage media, says Sriram Kosuri, a staff scientist at the Wyss Institute who also worked on the project.

The tome that got the honor of becoming the worlds first biological book is the forthcoming Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves. The book, coauthored by Church, will be published in more conventional forms this fall.

Similar approaches have been demonstrated before, but on a smaller scale. In 2001, Carter Bancroft and his colleagues at the Mount Sinai School of Medicine encoded in DNA the opening lines of Charles Dickenss A Tale of Two Cities. A 2010 project from the J. Craig Venter Institute encoded a 7920-bit watermark in a bacterium genome sequence. Churchs paper, however, takes us from a few bits to many megabits, says Jacobson. If you have a big enough quantitative advance, at some point theres a qualitative shift, and Id say thats the case here.

But another researcher who studies the intersection of biology and technology and asked to remain anonymous calls Churchs paper a silly vanity project with little value. Its like showing you could painstakingly use an abacus to solve a Hamiltonian path problem that would take the average computer a microsecond, he says. Other than maybe military intelligence, finding real-world applications for DNA storage technology under no conceivable set of circumstances is even remotely likely, he says.

View original post here:
Reading and Writing a Book With DNA

Posted in DNA

An Entire Book Written in DNA

DNA can be used to store information at a density about a million times greater than your hard drive, report researchers in Science today. George Church of Harvard Medical School and colleagues report that they have written an entire book in DNA, a feat that highlights the recent advances in DNA synthesis and sequencing.

The team encoded a draft HTML version of a book co-written by Church called Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves. In addition to the text, the biological bits included the information for modern formatting, images and Javascript, to show that DNA (like other digital media) can encode executable directives for digital machines, they write.

To do this, the authors converted the computational language of 0's and 1's into the language of DNA--the nucleotides typically represented by A's, T's G's and C's; the As and Cs took the place of 0's and Ts and Gs of 1's. They then used off-the-shelf DNA synthesizers to make 54,898 pieces of DNA, each 159 nucleotides long, to encode the book, which could then be decoded with DNA sequencing.

This is not the first time non-biological information has been stored in DNA, but Church's demonstration goes far beyond the amount of information stored in previous efforts. For example, in 2009, researchers encoded 1688 bits of text, music and imagery in DNA and in 2010, Craig Venter and colleagues encoded a watermarked, synthetic genome worth 7920 bits.

DNA synthesis and sequencing is still too slow and costly to be practical for most data storage, but the authors suggest DNAs long-lived nature could make it a suitable medium for archival storage.

Erik Winfree, who studies DNA-based computation at Caltech and was a 1999 TR35 winner, hopes the study will stimulate a serious discussion about what roles DNA can play in information science and technology.

The most remarkable thing about DNA is its information density, which is roughly one bit per cubic nanometer, he writes in an email.

Technology changes things, and many old ideas for DNA information storage and information processing deserve to be revisited now -- especially since DNA synthesis and sequencing technology will continue their remarkable advance.

The rest is here:
An Entire Book Written in DNA

Posted in DNA

Book converted to DNA then 'read' to show off bio-digital storage

6 hrs.

Francie Diep , InnovationNewsDaily

Bioengineers have turned a book into DNA. The researchers also have shown they can decode the DNA to re-create the book, which includes 53,426 words, 11 images and one interactive Javascript app.

This may be the world's only modern biology book that costs thousands of dollars to read as well as write.

The new bio-digital book, coded from a Harvard University researcher's writings on synthetic biology, represents the largest amount ofdata ever written into DNA. Because of how costly and complex it is to read and write genetic material, DNA is still far from a practical storage drive. Yet as the price of synthesizing and sequencing DNA continues to drop, it may become an interesting way of storing data for the very long term, said Sriram Kosuri, a Harvard bioengineer who was one of the bio-digital book's creators.

"It brings a different perspective into the storage field," Kosuri told InnovationNewsDaily.

"At this point, it's very premature to hope that it would actually become something practical," said Stefano Lonardi, a computational biologist at the University of California, Riverside, who was not part of the Harvard effort. Nevertheless, Lonardi said, the work is a step toward DNA storage in the future. "These are things that people have to do first in order to get to something practical," he said.

Turning an e-book into DNATo turn text and pictures into a double helix, the book had to undergo several translations. First, Kosuri and his colleagues wrote an HTML file of a draft of the book that Harvard bioengineer George Church was writing at the time. HTML is the language Web developers use to write websites.

The biologists then turned the HTML into binary, the 1s and 0s that computers read. They decided to use the individual building blocks of DNA, commonly referred to by their one-letter initials, to represent the 1s and 0s. The building blocks A and C would represent 0s, they decided, while G and T would represent 1s. They then assembled strands of DNA representing their binary code. [10 Technologies Poised to Transform our World]

One of the greatest challenges of building DNA from scratch is that it's expensive and difficult to create long, unbroken strings of the stuff. So Kosuri and his teammates decided they would make very many smaller pieces instead, tagging each piece with an address so that someone trying to read the strands would be able to put them in the correct order. Such pieces are easy for the latest DNA-reading technology, callednext-generation sequencing, to process.

See original here:
Book converted to DNA then 'read' to show off bio-digital storage

Posted in DNA

‘Nanojackets’ for treating breast cancer could be game changer for cancer care

A novel nanotechnology drug delivery system under development to infiltrate breast cancer tumors could pave the way for treating other diseases.

Penn State College of Medicine received a $1 million grant from a state research fund set up with money from its tobacco settlement to assess the drug treatments commercialization potential.

The principal investigator for the nanotechnology delivery system is Mark Kester, a professor of pharmacology and director of the Penn State Center for NanoMedicine and Materials. He has been working for the past five to six years with Jim Adair of Penn States department of material sciences and engineering, and Keystone Nano, a nanotechnology company spun out of Penn State University led by Jeff Davidson, the founder of the Biotechnology Institute and Pennsylvania Bio industry association.

The next generation of cancer-fighting drugs specifically target cancer proteins rather than attack cancer and noncancer cells indiscriminately. Although companies have recognized the ability of small interfering RNA as a small molecule that can be directed to interfere with the production of cancer cells, the toxicity of siRNA has proved a challenge in its use. Biotechnology companies and institutions have been studying ways to use different nanotechnology particles to house the toxic molecule.

In an interview with MedCity News, Kester explained that the team has developed nontoxic nanojackets that use calcium phosphocillate nanoparticles, material that makes up teeth and bones, to deliver the toxic siRNA safely to the gene mutation. In this case, the one that causes overexpression of an oncogenic protein in breast cancer patients.

Getting to this stage has taken five to six years. Kester estimates it will take another one-and-a-half years to get to the point where it will have enough data to submit an IND application. During that time it will work with contract research organizations across Pennsylvania to conduct preclinical trials using the nanojackets.

Even if the companys IND application is approved, it will take another five to eight years to get the technology to the point where it can be submitted for FDA approval.

A cursory search on Clinicaltrials.gov revealed that 10 clinical studies are using siRNA to combat diseases in clinical trials. The one that is using them to fight breast cancer uses fat cells to house the toxic molecule.

If successful, the siRNA molecule could theoretically be delivered to any protein mutation and destroy it, a development that would revolutionize not only cancer treatment but one that could lead to treating Alzheimers and Parkinsons disease and other unmet needs.

Link:
‘Nanojackets’ for treating breast cancer could be game changer for cancer care

Officials continue to push for chip fab manufacturer

There still is no decision from the Army Corps of Engineers about key preparations for land being marketed to nanotechnology companies as a chip fabrication site.

But local economic development officials say the process has become a race against time, as the multi-billion dollar industry ramps up for a shift in the way chips are produced.

We think the next site selection will be in 2013 and 2014, said Mohawk Valley EDGE economic development agency President Steve DiMeo. The major players and some of the support industry (are) talking about timelines for actually building and having output from a 450 mm plant.

DiMeo was referring to the new generation of nanotechnology chips, which will be made in a new 450 mm format.

Currently, most of the chips, which can be found in everything from cell phones to medical devices, are made many at a time on 300 mm wafers. Companies now want to make them on 450 mm wafers, so more of the tiny chips can be manufactured at once.

In September 2011, New York Gov. Andrew Cuomo announced $4.4 billion in private investment in nanotechnology initiatives in New York state.

That was in addition to the 2009 announcement that $45 million in state funds would be spent at SUNYIT to create a state of the art nanotechnology research and development compound.

Those investments are hoped to up the appeal of the Marcy site, which has been on the market for more than a decade. So far, about $16 million has been spent to prepare the site. A total of $39 million in work is planned.

Long time coming

The tussle with the Army Corps has been going on almost as long as the SUNYIT-owned site has been marketed to the nanotechnology industry.

Go here to read the rest:
Officials continue to push for chip fab manufacturer

Cooper Medical School of Rowan University sends new students exploring through Camden

To acquaint Cooper Medical School of Rowan Universitys first 50 students with their new neighborhood, the charter class was loosed upon Camden on Wednesday with a series of clues in search of specific landmarks the good, the bad and the ugly.

For new students Susan Talamini and Rebecca Lee, the first and most crucial item they needed to locate was their car in the parking garage across the street from the new school.

But, like the proverbs will tell you, its about the journey, not the destination.

The women realized that sooner than later.

Talamini, 28, and Lee, 26, are both from out of town.

Complete strangers to each other before orientation at the school this week, Talamini and Lee had to learn to work together quickly as a team.

Talamini was born in Essex County in New Jersey, and Lee is from Cleveland, Ohio.

Both women spent a good amount of their lives in New York and now live in Princeton and Haddonfield.

Something else the pair has in common?

They were two of 50 students chosen out of 2,900 applicants to be the first to attend Cooper Medical School.

Go here to read the rest:
Cooper Medical School of Rowan University sends new students exploring through Camden

New Jersey Medical School Researchers Develop DNA Sequencing Tests for Hereditary Diseases

Newswise NEWARKScientists at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS) have developed new DNA sequencing tests that hold significant promise for decreasing costs associated with diagnosing cancer and hereditary diseases, including cysticfibrosis.

Officials at the New Jersey Department of Health approved the use of the new Cystic Fibrosis (CF) Carrier and Diagnosis Test, which was created at the Institute for Genomic Medicine at UMDNJ-NJMS. Using a semiconductor mechanism that was developed by San Francisco-based Ion Torrent, the microchip tests the entire gene for mutations. IGM now offers this certified Clinical Diagnostic Laboratory service for hospitals as well as obstetrics and gynecology practices throughout the Garden State.

According to the Cystic Fibrosis Foundation web site, More than 10 million Americans are symptomless carriers of the defective CF gene. This chronic disease impacts the lungs and the digestive system. It occurs when a child inherits one defective CF genefrom each parent. Statistics show New Jersey averages 125,000 births of children who are diagnosed with cystic fibrosis annually.

We believe the adaptation of this new sequencing technology will drastically improve our ability to analyze genetic disorders, said Marvin N. Schwalb, PhD, director of the Institute for Genomic Medicine. Traditional CF sequencing testing costs thousands of dollars making the test unavailable for carrier screening. This new test costs less than $200. Most importantly, the genetic carrier test we developed improves the diagnosis rate to 98 percent. While the test provides significant improvement for all populations, the improved rate is particularly valuable for minorities because current carrier screening methods only detects approximately 65% of mutations in these populations.

The new technology provides many advances including the ability to test as many as 96 samples on a single platform and the fact that the equipment cost 1/10 as much as the previous technology.

IGM has developed another test, which was also approved by the NJHSS, for mitochondrial DNA. Mutations in mitochondria cause a wide variety of diseases, such eye and neuromuscular system disorders and possible cancer.

Schwalb, a professor of Pediatrics, Microbiology and Molecular Genetics at NJMS, said, We are proud of the fact that the IGM is a world leader in the advancement of genetic diagnosis. DNA sequencing will keep us very busy for a while. In the state of New Jersey, there is nothing thatcompares to this advancement and this is just the beginning.

To arrange an interview with Dr. Marvin Schwalb, contact Kaylyn Kendall Dines at 973-972-1216.

About New Jersey Medical School:

Founded in 1954 as the Seton Hall College of Medicine and Dentistry, UMDNJNew Jersey Medical School was the state's first medical school. Today, it is part of the University of Medicine and Dentistry of New Jersey. NJMS has four mission areas: education, research, clinical care, and community outreach. It has 22 academic departments and more than 60 centers and institutes. In addition to offering the MD degree to its students, NJMS also offers, MD/PhD, MD/MPH, and MD/MBA degrees through collaborations with other institutions of higher education.

View post:
New Jersey Medical School Researchers Develop DNA Sequencing Tests for Hereditary Diseases

UCR Medical School: Funding bill stalls in committee

Posted on | August 16, 2012 | Comments

UC Riverside School of Medicine Research Building

Legislation that would give the UC Riverside Medical School $15 million finally made it to committee Thursday, quickly stalled, and is likely dead for the year.

The bill by Assemblyman Jeff Miller, R-Corona, emerged earlier this summer and had co-authors from across Inland Southern California. It proposed to allocate $15 million to help open the medical school from the states expected settlement of an overbilling case with the Senior Care Action Network (SCAN.)

The bill idled in the Senate Rules Committee for several weeks. Thursday, it was referred to the Senate Appropriations Committee, where majority Democrats voted to place it on the suspense file. Later, it was among dozens of bills left on suspense.

There are significant costs, the panels chairwoman, state Sen. Christine Kehoe, D-San Diego, said during the hearing.

Miller is the Republican candidate for Riverside Countys 31st Senate District, a top fall target of Senate Democrats. In a statement a short while ago, Miller blamed partisan politics for the bills demise.

It is extremely disappointing to see Sacramento Democrats put partisan politics first and block the vital funding needed to get the UC Riverside Medical School off the ground, said Miller. Its clear that the political bosses are more interested in playing political games than improving health care.

Earlier, Senate President Pro Tem Darrell Steinberg, D-Sacramento, denied that the SD-31 race had anything to do with the bill.

My thoughts are it is premature and there ought to be a public-policy discussion about how to spend those proceeds, he said of the SCAN settlement. Without mentioning Miller, Steinberg alluded to legislative Republicans blanket opposition to new tax revenue.

Original post:
UCR Medical School: Funding bill stalls in committee

Alfa Wassermann Diagnostic Technologies' ACE Axcel System Applies Smart Technology to Enhance and Simplify Physician …

WEST CALDWELL, N.J., Aug. 16, 2012 /PRNewswire/ -- Alfa Wassermann Diagnostic Technologies, LLC (AWDT), the market leader in clinical chemistry analyzers for the physician office laboratory, today announced the launch of its ACE Axcel Clinical Chemistry System. The next generation ACE Axcel is designed to meet the needs of physician office laboratories and is cleared by the US Food and Drug Administration specifically for use in physician office labs.

(Photo: http://photos.prnewswire.com/prnh/20120816/NY58283)

The ACE Axcel is an easy-to-operate system that produces quality results covering a range of the most widely tested conditions. It adds touch screen functionality, an intuitive user interface and Internet connectivity to make in-office laboratory testing faster, more convenient and more cost-effective. The system has an easy-to-use graphical user interface and touch screen technology for intuitive control. Built-in Internet connectivity facilitates technical support, remote access and laboratory integration, and provides seamless connection to electronic health records using AWDT's Alfa LIS (Lab Information System) or other laboratory information systems.

"Our new ACE Axcel system builds on the quality and reliability of our market leading clinical chemistry systems to provide unparalleled ease-of-use, accuracy and efficiency to physician office laboratories," said Peter J. Napoli, President of Alfa Wassermann Diagnostic Technologies."Intuitive touch screen technology and Internet connectivity streamline laboratory operations, increasing productivity and maximizing the potential for the lab to contribute to the financial health of the practice, while providing patients with the medical and convenience benefits of on-site laboratory testing."

The ACE Axcel is a self-contained system in a small footprint that can process up to 285 tests per hour with both photometric and potentiometric detection technologies.It can run any combination of single tests, panels or profiles from a comprehensive test menu, and has an open reagent system that enables custom assays.A STAT interrupt feature allows users to load and prioritize STAT samples during system operation to meet immediate diagnosis and treatment needs.

Dr. John Chafos of Family Care Medical Practice in Green Brook, NJ, who evaluated the ACE Axcel, commented, "Physician office testing provides benefits to both patients and healthcare providers, and we found that the ACE Axcel system makes it easier than ever to incorporate diagnostic testing into our practice. Features such as the touch screen control panel, high degree of automation, and reduction of sample and reagent handling have the potential to increase the productivity of our lab operations. In addition, Internet connectivity will enable a higher level of technical support, a valuable benefit for our medical technologists."

The ACE Axcel includes a number of features that automatically ensure accurate results.Closed-tube sampling with the STEP module minimizes operator interaction with patient specimens, making for a safer workplace. System calibration is automatically monitored on an ongoing basis.Web-enabled Alfa Assist technical support is available 24/7 and maximizes instrument uptime. Liquid, ready-to-use reagents eliminate operator prep time. The on-board reagent refrigeration feature maintains specimen and reagent integrity and decreases handling. In addition, reagent inventory is automatically managed by the system.

Trip Trepagnier, Vice President of Marketing & Business Development for AWDT noted, "ACE Axcel automates and simplifies the testing process, while our nationwide network of award-winning service and support personnel ensures that our customers can rapidly deliver high quality diagnostic test results with maximum productivity and minimum hassle. We believe the ACE Axcel system will be welcomed by our large established customer base, as well as by physicians who are concerned about the complexity and technical challenges of conventional diagnostic testing systems."

Alfa Wassermann Diagnostic Technologies, LLC is a leading provider of clinical diagnostic instrumentation and reagents. AWDT focuses on the needs of physician office laboratories and veterinary clinics. Alfa Wassermann's diagnostic products include the high-performance, low-maintenance ACE Alera, Vet Alera and Alfa LIS, which are sold worldwide to physician, veterinary and research laboratories.

For more information on the ACE Axcel, visit http://www.ACEAxcel.com.

Visit link:
Alfa Wassermann Diagnostic Technologies' ACE Axcel System Applies Smart Technology to Enhance and Simplify Physician ...

2012 Pacific Rim Summit On Industrial Biotechnology And Bioenergy

The Biotechnology Industry Organization (BIO) today announced more than 100 speakers covering the latest in industrial biotechnology at the 2012 Pacific Rim Summit on Industrial Biotechnology and Bioenergy. The Summit will present four plenary sessions featuring international executives and academic leaders in industrial biotechnology October 10-12 at the Westin Bayshore in Vancouver, Canada.

Vancouver is an ideal location for this years conference with its fast-growing and successful life sciences and biotech industries and a robust forest biomass supply, said Brent Erickson, executive vice president for BIOs Industrial & Environmental Section. Our outstanding line-up of plenary sessions will highlight the growing biobased economy as we learn about advances in biofuels, renewable chemicals and synthetic biology. Industrial biotechnology can reduce dependence on foreign oil and also benefits consumers by revitalizing manufacturing and creating new opportunities for agriculture, generating jobs, making greener products and cleaner processes.

Plenary sessions include:

Status Report: The Synthetic Biology Pathway to Innovation in Fuels and Chemicals Wednesday, October 10, 12 2:15PM

Flying green: Why Airlines See a Bright Future in Biofuels Thursday, October 11, 8 9:30AM

Overcoming Regional Biomass Feedstock Supply Challenges with Public Policy and Science Thursday, October 11, 11:30AM 1:45PM

Biotechnology and Renewable Chemicals: The Future is Now Friday, October 12, 10AM 12PM

Now in its seventh year, the Pacific Rim Summit on Industrial Biotechnology and Bioenergy will address the latest issues in industrial biotechnology, including algae, advanced biofuels, biopolymers and bioplastics, dedicated energy crops, green chemistry, and synthetic biology. The annual Pacific Rim Summit is the original conference dedicated solely to growth of the industrial biotechnology sector in Asia and the Americas. Visit http://bio.org/pacrim.

About BIO BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Source: BIO (Biotechnology Industry Organization)

More here:
2012 Pacific Rim Summit On Industrial Biotechnology And Bioenergy

11th Annual BIO Investor Forum to Highlight Venture-Stage Growth and Emerging Public Companies

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announces that registration is now available for the 11th Annual BIO Investor Forum, an international biotech investor conference focused on investment strategies for early stage and established private companies as well as emerging public companies. The event will take place October 9-10, 2012 at the Palace Hotel in San Francisco, Calif.

The BIO Investor Forum is the ideal venue for investors and business development leaders to discuss financial and strategic business issues affecting investment in biotech companies, and explore potential partnerships and business collaborations to fuel research and development for promising innovation, said Alan Eisenberg, executive vice president, Emerging Companies & Business Developmentat BIO.

The 2011 BIO Investor Forum scheduled almost 900 meetings, 88% of which were between biotech companies and investors. Furthermore, the event hosted nearly 120 late-stage private and emerging public company presentations.

This years event will assemble public and venture-stage growth companies, as well as top public and private equity investors, to explore investment trends and opportunities in life sciences. In addition to panel discussions led by clinical thought leaders focusing on industry trends, the conference features business roundtables focused on financing, investment and the latest M&A trends. BIO One-on-One Partnering will also provide an opportunity to arrange meetings between investors; companies; and industry business development, licensing and therapeutic franchise heads.

The BIO Investor Forum is a must attend event forpublic and private market investors, research analysts, investment bankers, and industry executives focused on investment and business development opportunities in the life sciences.

The meeting attracts healthcare venture capital and public market investors and research analysts. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and biotechnology companies.

BIO and the BIO Investor Forum Advisory Committee set the event agenda and program. Advisory Committee members include:

To learn more about the BIO Investor Forum, including registration and program information, please visit here.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including Supporting Banks Stifel, Nicolaus & Company, and Roth Capital. BIO Double Helix and Helix Sponsors include Abbott Biotech Ventures, Amgen Ventures, Baxter Ventures, J&J Development Corporation, MedImmune Ventures, GlaxoSmithKline, Merck, and Pfizer.

Link:
11th Annual BIO Investor Forum to Highlight Venture-Stage Growth and Emerging Public Companies

Spoiler Chat: Scoop on Grey's Anatomy, Smash, Teen Wolf, Private Practice and More!

Tamie in St. Louis: I can't take not knowing if they are killing Eric Dane off Grey's! Any idea what the plan is? Well, we're not going to sugarcoat it, but when we spoke to Chandra Wilson, it didn't sound good. Mostly because she was talking about taking care of him and "stroking" him (we assume his face) in the beginning of the season. "I really appreciate the way that we have taken care of him in the beginning of the season," Wilson tells us. "I think it's something that Grey's fans will really appreciate. We get to stroke him a lot in the beginning of our season." However, she assured us that someone who is gone from the show will not be forgotten. "It doesn't matter if the characters aren't there anymore. We just talk about him all the time!" she laughs. Let's hope they aren't using past tense when talking about McSteamy.

Ben in Chicago: I've been missing your Smash coverage! Cannot wait until it returns, so can I have a bit of scoop for now to hold me over until 2013? Doesn't the second season of Smash seem so far away? It's unbearableuntil we wiggled our way onto the set and got some awesome scoop! More on that later, but for now, here are some tidbits we can reveal: a mosh pit, an unexpected relationship between Jennifer Hudson's character and Ivy, Tom large and in charge and finallyKaren is in looove!

Check out an extremely sexy (and leggy!) Kate Hudson on Glee

Beth: I'm so bummed that Tim Daly won't be back on Private Practice. Will his exit be addressed on the show? We're sad to see him go, too, and yes, his absence will definitely be felt on the show, especially by Violet. "My character at the beginning of the season, it's all about loss," Amy Brenneman tells us. "Tim is not coming back, and that's pretty much what I'm dealing with." As for Daly's exit, Brenneman says, "It's like life. People come, and then they go, and then [they] write to it. It gets to be like real living."

Cece: I'm so sick of the Liam-Silver-Navid love triangle on 90210! Is there any hope for us Liam and Annie fans? There's always hope! At least, that's what Matt Lanter says of the fan-favorite couple's future. "I didn't know there were so many Liam and Annie fans! Every time Liam tries to get together with some other girl, all I hear about is Liam and Annie on my Twitter and stuff," he says. "I think there is always hope for it. We'll see how long the series runs. Maybe they'll get back together in the end of the series. We got to wait for it!" We advise against holding your breath, people, it may be a while!

Continued here:
Spoiler Chat: Scoop on Grey's Anatomy, Smash, Teen Wolf, Private Practice and More!

DNA Sample Concentrator uses centrifugal force and vacuum.

August 16, 2012 - With built-in, removable diaphragm pump, CentriVap DNA Centrifugal Concentrator processes DNA samples and other minute quantities of solvents. Up to 60, 1.5 mL and 72, 0.5 mL micro centrifuge tubes may be processed simultaneously. There are 9 user-set programs accessible via buttons, and Quick-Start(TM) One Button Start Up function starts rotor, heater, timers, and vacuum pump. Along with Quick-Stop(TM) Rotor Brake, features include inlet and exhaust traps and optional CentriZap Strobe Light. Original Press release Labconco Corp. 8811 Prospect Ave. Kansas City, MO, 64132 2696 USA The CentriVap DNA Centrifugal Concentrator processes DNA samples and other minute quantities of solvents. Up to 60 each 1.5 ml and 72 each 0.5 ml micro centrifuge tubes may be processed at once.

With a built-in, removable diaphragm pump, the CentriVap DNA Concentrator has 9 user-set programs accessible with the touch of a few buttons. The Quick-Start(TM) One Button Start Up starts the rotor, heater, timers and vacuum pump. Three Quick-Start Buttons store one user-set program each. The Quick-Stop(TM) Rotor Brake stops vacuum within seconds to open the valve and bleed air into the chamber. Separate heat and run times allow the heat to be turned off sooner than the rotation to protect heat sensitive samples from excessive heat exposure. The Run Time turns off all functions after the set period of time has expired. Both an inlet trap to collect liquid coming off the samples and an exhaust trap to collect liquid coming off the pump exhaust are included. An optional CentriZap Strobe Light which utilizes a flashing light the same frequency as the rotation of the rotor allows remaining samples to be viewed in either sample tube or microtiter plate while it is spinning.

For more information on the CentriVap DNA Concentrator and the rest of the CentriVap line, contact Labconco at 800-732-0031, or download the PDF brochure at http://www.labconco.com.

Remcom provides electromagnetic simulation and wireless propagation software and services. Our products are used for antenna design, photonics and optics, MRI, microwave circuits, RFID, military and defense applications, and more.

Learn more...

If you are a printer you can easily print on magnets! As a manufacturer of flexible magnetic materials, Magnum Magnetics has different options for you and your customers. We have magnets that will work for Digital, Offset, Flexo, Inkjet and Screen.

Visit Magnum Magnetics

Available For a Limited Time Only On a short-lead time, expedited delivery basis for standard frequencies. 10.0, 14.4, 20.0, & 40.0 MHz Models HCMOS or Clipped Sine Output +3.3V or +5.0V Supply Tight Stability from -40 to +85C Ruggedized 5 x 7mm package 500pc Reel Sizes Competitive Pricing Download T75 Specification Sheet

Visit Greenray Industries

Getting a medical-grade foot control customized to your specifications need not require any NRE/tooling costs nor months of development. Many OEM requirements can be effectively addressed using our array of proven foot control components.

More here:
DNA Sample Concentrator uses centrifugal force and vacuum.

Posted in DNA

DNA Dynamics Announce SLAM Engine Overhaul

LEAMINGTON SPA, England, Aug. 16, 2012 /PRNewswire/ --DNA Dynamics, Inc. (OTC Pink: DNAD), a global developer and publisher of mobile video games and applications, today announced that the latest iteration of it's SLAM Engine Technology, SLAM V7.0, is currently in development.

The SLAM Engine is DNA's powerful proprietary technology on which all of its internally developed games are built. SLAM 6.x has been in use over the last 18 months however the gaming world has moved on in that time. The SLAM Engine has always been focused on delivering games on multiple platforms over a short development cycle and SLAM 7.0 takes this ethos to the next level. Built around the popular programing language of C# and the Mono Framework SLAM 7.0 will see DNA's next batch of games move on from both technical and time to market standpoints

Ed Blincoe, CEO of DNA Dynamics Inc., commented, "Redeveloping the SLAM Engine has been a major undertaking for the team however it was critical we keep ahead of the pack in terms of our development processes and time to market. Our next game is currently being built upon the new technology base and we've already seen a marked improvement in game performance and build speed, I'm excited about what we can achieve using the new SLAM Engine and the games it will produce." Blincoe continued, "By utilizing our own technology we can substantially reduces our development costs making us a company to watch into 2013."

The DNA Studios Team is currently transitioning over to the new technology base and expects to have its first game to market before the end of the year.

About DNA Dynamics, Inc.Headquartered in Leamington Spa in the United Kingdom, DNA Dynamics is a worldwide developer and publisher of graphically rich, interactive entertainment currently delivered on iOS, Android, Apple Mac and PC. Through its operating subsidiaries, the Company has created, acquired or licensed a portfolio of highly recognizable or emerging brands that broadly appeal to its consumer demographics, ranging from children to adults and casual gamers to serious enthusiasts. For more information, please go to http://www.dnadynamics.net.You can also follow the Company on Facebook and Twitter.

For more information please email info@dna-interactive.com.

Forward-Looking StatementsThis press release may contain forward-looking statements, including information about management's view of DNA Dynamics, Inc.'s future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of DNA Dynamics, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on DNA Dynamics' future results. The forward-looking statements included in this press release are made only as of the date hereof. DNA Dynamics cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, DNA Dynamics undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by DNA Dynamics.

Read the original post:
DNA Dynamics Announce SLAM Engine Overhaul

Posted in DNA

Spoiler Chat: Scoop on Grey's Anatomy, Smash, Teen Wolf, Private Practice and More!

Tamie in St. Louis: I can't take not knowing if they are killing Eric Dane off Grey's! Any idea what the plan is? Well, we're not going to sugarcoat it, but when we spoke to Chandra Wilson, it didn't sound good. Mostly because she was talking about taking care of him and "stroking" him (we assume his face) in the beginning of the season. "I really appreciate the way that we have taken care of him in the beginning of the season," Wilson tells us. "I think it's something that Grey's fans will really appreciate. We get to stroke him a lot in the beginning of our season." However, she assured us that someone who is gone from the show will not be forgotten. "It doesn't matter if the characters aren't there anymore. We just talk about him all the time!" she laughs. Let's hope they aren't using past tense when talking about McSteamy.

Ben in Chicago: I've been missing your Smash coverage! Cannot wait until it returns, so can I have a bit of scoop for now to hold me over until 2013? Doesn't the second season of Smash seem so far away? It's unbearableuntil we wiggled our way onto the set and got some awesome scoop! More on that later, but for now, here are some tidbits we can reveal: a mosh pit, an unexpected relationship between Jennifer Hudson's character and Ivy, Tom large and in charge and finallyKaren is in looove!

Check out an extremely sexy (and leggy!) Kate Hudson on Glee

Beth: I'm so bummed that Tim Daly won't be back on Private Practice. Will his exit be addressed on the show? We're sad to see him go, too, and yes, his absence will definitely be felt on the show, especially by Violet. "My character at the beginning of the season, it's all about loss," Amy Brenneman tells us. "Tim is not coming back, and that's pretty much what I'm dealing with." As for Daly's exit, Brenneman says, "It's like life. People come, and then they go, and then [they] write to it. It gets to be like real living."

Cece: I'm so sick of the Liam-Silver-Navid love triangle on 90210! Is there any hope for us Liam and Annie fans? There's always hope! At least, that's what Matt Lanter says of the fan-favorite couple's future. "I didn't know there were so many Liam and Annie fans! Every time Liam tries to get together with some other girl, all I hear about is Liam and Annie on my Twitter and stuff," he says. "I think there is always hope for it. We'll see how long the series runs. Maybe they'll get back together in the end of the series. We got to wait for it!" We advise against holding your breath, people, it may be a while!

Continued here:
Spoiler Chat: Scoop on Grey's Anatomy, Smash, Teen Wolf, Private Practice and More!

Psychics Universe, a New Online Spirituality Network, Announces Why 12/21/12 Will Not Be the End of the World

Psychics Universe regularly discusses issues of personal wellbeing and spirituality. In this new discussion, they address the questions of “Will 12/12/2012 be the end of the world?”Los Angeles, CA (PRWEB) August 16, 2012 Due to the recent buzz in internet chat rooms and message forums about Mayan prophecies and ancient calendars, PsychicsUniverse, a new online spirituality network, publicly ...

See the original post:

Psychics Universe, a New Online Spirituality Network, Announces Why 12/21/12 Will Not Be the End of the World

NASA goes green: NASA selects green propellant technology demonstration mission

NASA has selected a team led by Ball Aerospace & Technologies Corporation of Boulder, Colo., for a technology demonstration of a high performance "green" propellant alternative to the highly toxic fuel hydrazine. With this award, NASA opens a new era of innovative and non-toxic green fuels that are less harmful to our environment, have fewer operational hazards, and decrease the complexity and cost of launch processing.

Today's use of hydrazine fuel for rockets, satellites and spacecraft is pervasive. Hydrazine is an efficient propellant and can be stored for long periods of time, but it also is highly corrosive and toxic. NASA is seeking new, non-toxic high performance green propellants that could be safely and widely used by rocketeers, ranging from government to industry and academia. Green propellants include liquid, solid, mono- propellant, which use one fuel source, or bi-propellants, which use two, and hybrids that offer safer handling conditions and lower environmental impact than current fuels.

"High performance green propellant has the potential to revolutionize how we travel to, from and in space," said Michael Gazarik, director of NASA's Space Technology Program at NASA Headquarters in Washington. "An effective green rocket fuel would dramatically reduce the cost and time for preparing and launching space missions while decreasing pollution and harm to our environment."

Following a solicitation and peer-review selection process, NASA chose the Green Propellant Infusion Mission proposal and a team lead by Ball and co-investigators from the Aerojet Corporation in Redmond, Washington, the U.S. Air Force Research Laboratory at the Wright Patterson Air Force Base in Ohio, the U.S. Air Force Space and Missile Systems Center at the Kirkland Air Force Base in New Mexico, NASA's Glenn Research Center in Cleveland and NASA's Kennedy Space Center in Florida for the new mission.

NASA's Green Propellant Infusion Mission is expected to be developed and flown in approximately three years. The Space Technology Program will provide $45 million for the mission, with some additional cost-sharing by mission co-investigators.

This demonstration will bridge the gap between technology development and use of green propellant. The team will develop and fly a high performance green propellant, demonstrating and characterizing in space the functionality of the integrated propulsion system. Such a demonstration will provide the aerospace community with a new system-level capability for future missions.

Maturing a space technology, such as a revolutionary green propellant, to mission readiness through relevant environment testing and demonstration is a significant challenge from a cost, schedule and risk perspective. NASA's Technology Demonstration Missions Program performs this function, bridging the gap between laboratory confirmation of a technology and its inital use on an operational mission.

More information: For more information about NASA's Space Technology Program and Technology Demonstration Missions, visit: http://www.nasa.gov/oct

Provided by NASA

Read more:

NASA goes green: NASA selects green propellant technology demonstration mission

Can Markets Work in Medicine?

One of the sharpest dividing lines between conservatives and liberals is whether or not markets can work in medicine. Progressives admit to being “deeply suspicious of the claim that a health care system dominated by powerful vested interests and mystifying in its complexity can be tamed by consumers who are [...]

Follow this link:

Can Markets Work in Medicine?

Research and Markets: Personalized Medicine – A Global Market Overview

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/vxwrkb/personalized_medic) has announced the addition of the "Personalized Medicine - A Global Market Overview" report to their offering.

This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.

The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.

This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology.

The report covers the brief business profiles of 56 key global players and 77 major players across the United States - 45; Europe - 24; and Rest of World - 8.

The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.

For more information, including table of contents and list of companies mentioned, please visit http://www.researchandmarkets.com/research/vxwrkb/personalized_medic

Read more:

Research and Markets: Personalized Medicine - A Global Market Overview

Modernizing Medicine Launches EMA Dermatology With Visualdx at the American Academy of Dermatology's 2012 Summer …

BOCA RATON, FL--(Marketwire -08/16/12)- Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific EMR application, announced today the availability of EMA Dermatology with Logical Images' VisualDx, a comprehensive digital medical image library, proving the company's dedication to bringing dermatologists the most powerful EMR on the market.

Modernizing Medicine's user-friendly EMA features algorithms that help to improve medical decision making and information tracking, simplify billing and speed up medical documentation, saving physicians and their staff valuable time. In two years, Modernizing Medicine has captured over 10% of the dermatology market and is currently used by over 550 specialty-specific healthcare practices across the country.

Logical Images' VisualDx is a massively hyperlinked visual thesaurus of over 1,200 dermatology conditions represented by over 25,000 high-resolution medical images. VisualDx captures disease variation by age, body location, skin type, immune status, disease stage, disease severity, lesion type and more, showing how each might look at different stages and in people of different ages and ethnicities. VisualDx is especially helpful in identifying uncommon conditions.

The addition of VisualDx to Modernizing Medicine's powerful EMA Dermatology product will assist dermatologists further at point of diagnosis and promote patient engagement by sharing real medical images patients can relate to. Modernizing Medicine intends to make VisualDx available to all new and existing EMA Dermatology clients.

"I commend Modernizing Medicine for the EMA-VisualDx implementation. Now, in seconds dermatologists can access the best medical images in the world which will help in educating patients right in the exam room," said Art Papier, CEO of Logical Images. "VisualDx on the iPad is a great example of a novel technology that helps to create a bond between physician and patient. Patients have a hard time understanding our spoken medical language, but they easily understand pictures. Images are everything in dermatology, and EMA is now delivering the best medical image collection through VisualDx in seconds. It speeds practice and helps patients. That is what busy physicians want."

"We're confident that the addition of Local Images' VisualDx to EMA Dermatology will help dermatologists make more accurate and complete diagnoses and treatment plans for their patients and will save them and their staff even more time than EMA already does," says Modernizing Medicine co-founder and dermatologist Michael Sherling. "The addition demonstrates our dedication to the dermatology market and the development of the most valuable technology for specialty-specific practices."

EMA Dermatology demos complete with the new VisualDx feature will be available at the Modernizing Medicine booth, #809, during the Summer AAD meeting in Boston this week. Modernizing Medicine will also host a cocktail reception for its customers and press on August 17th, at Top of the Hub, which will feature a presentation by coding, documentation and reimbursement expert, Inga Ellzey. If you'd like to attend, please reach out to Chelsea Boudreaux, at chelsea.boudreaux@atomicpr.com.

About Modernizing MedicineModernizing Medicine is delivering the next generation of electronic medical records (EMR) technology for the healthcare industry. Our product, Electronic Medical Assistant (EMA), is a cloud-based specialty-specific EMR with a tremendous amount of medical content already built-in that saves physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with over 400 different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, and optometry markets, and to more than 550 practices across the country.

About Logical ImagesBased in Rochester, NY, Logical Images develops visual health care tools to elevate diagnostic accuracy, enhance medical education, and heighten patient knowledge. Selected by Modern Healthcare Magazine as one of the "Best Places to Work in Healthcare" in 2009, Logical Images is a company of digital imaging experts, leaders in computer-based design and knowledge management, skilled image archivists, and practicing physicians. The company's products include VisualDx, a visual clinical decision support system for diagnostic accuracy, and Skinsight, an online consumer skin health and wellness resource. Logical Images has developed the most comprehensive digital medical image library including 60,000 images representing all ages and skin types. This extensive collection is the foundation for both the VisualDx professional tool and the Skinsight consumer tool -- designed to speed disease recognition for faster, more accurate decision making and patient understanding.

Visit link:

Modernizing Medicine Launches EMA Dermatology With Visualdx at the American Academy of Dermatology's 2012 Summer ...